Daiichi Sankyo to Colaborate with Merck KGaA and Pfizer in Development...

This week Daiichi Sankyo confirmed a clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate trastuzumab deruxtecan*, an antibody-drug conjugate or...

Study Confirms Local Radiotherapy to Improve Survival in Metastatic Prostate Cancer

According to recent data from the American Cancer Society, about 1 in 9 men will be diagnosed with prostate cancer during his lifetime and...

Addition of Pelvic Lymph Node Radiation may Significant Improve Prostate Cancer...

Initial reports from a large international clinical trial suggest that, in the treatment of man with prostate cancer that recurs after prostatectomy, the surgical...

Cetuximab Causes Less Side Effects and May be a Good Treatment...

Over the last decades human papilloma virus (HPV-) positive throat cancer incidence is rapidly increasing worldwide while the incidence of head and neck squamous...

Study Shows Zoledronic Acid Improves Disease-free Survival in Premenopausal HR+ early...

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen...

Pembrolizumab Improves Survival of Patients with Metastatic or Recurrent Head and...

Late-breaking results from the KEYNOTE-048 study (NCT02358031) reported at the annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich,...

Real-World Pancreatic Cancer Data Similar to Dosing Patterns Seen in Pivotal...

Results from a retrospective, observational analysis examining the real-world dosing patterns of patients with metastatic pancreatic cancer (mPC) treated with irinotecan liposome injection (Onivyde®,...

Nivolumab + Low-dose Ipilimumab may be First Line Treatment in Some...

Immunotherapy with nivolumab (Opdivo®; Bristol-Myers Squibb Company) and low-dose ipilimumab (Yervoy®; Bristol-Myers Squibb Company) could become a new first line treatment in patients with...

Combination of DKN-01 and Pembrolizumab in Esophagogastric Cancer Shows Promise

Clinical data from from an ongoing Phase I/II study of DKN-01, being developed by Leap Therapeutics, in combination with pembrolizumab (Keytruda®; Merck/MSD) in patients...

Encouraging Results for [Fam-] Trastuzumab Deruxtecan in HER2 Expressing Advanced Colorectal...

Updated Phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody-drug conjugate or ADC, were presented at the...

Latest